{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:16:24Z","timestamp":1790424984550,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K17164"],"award-info":[{"award-number":["19K17164"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12149-021-01706-4","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:03:25Z","timestamp":1642291405000},"page":"319-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia\/lymphoma in vivo"],"prefix":"10.1007","volume":"36","author":[{"given":"Yoichi","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-7460","authenticated-orcid":false,"given":"Sho","family":"Koyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Suzukida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitaro","family":"Kidera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takero","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneo","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,16]]},"reference":[{"issue":"25","key":"1706_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1706_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481\u201392.","journal-title":"Blood"},{"issue":"8","key":"1706_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837\u201342.","journal-title":"J Clin Oncol"},{"issue":"10 Pt. 1","key":"1706_CR4","first-page":"3625","volume":"9","author":"T Ishida","year":"2003","unstructured":"Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt. 1):3625\u201334.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1706_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192\u2013204.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1706_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/intimm\/dxu079","volume":"27","author":"O Yoshie","year":"2015","unstructured":"Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27(1):11\u201320.","journal-title":"Int Immunol"},{"issue":"6","key":"1706_CR7","first-page":"770","volume":"12","author":"SA Antoniu","year":"2010","unstructured":"Antoniu SA. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010;12(6):770\u20139.","journal-title":"Curr Opin Mol Ther"},{"issue":"4","key":"1706_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4161\/mabs.20996","volume":"4","author":"A Beck","year":"2012","unstructured":"Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs. 2012;4(4):419\u201325.","journal-title":"mAbs."},{"issue":"9","key":"1706_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","volume":"72","author":"JM Subramaniam","year":"2012","unstructured":"Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72(9):1293\u20138.","journal-title":"Drugs"},{"issue":"5","key":"1706_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/cas.12116","volume":"104","author":"T Ishida","year":"2013","unstructured":"Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma. Cancer Sci. 2013;104(5):647\u201350.","journal-title":"Cancer Sci"},{"issue":"28","key":"1706_CR11","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426\u201333.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1706_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2326-6066.CIR-15-0303","volume":"4","author":"H Ureshino","year":"2016","unstructured":"Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N, et al. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016;4(8):644\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"1706_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1706_CR14","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/cncr.23077","volume":"110","author":"FM Iwamoto","year":"2007","unstructured":"Iwamoto FM, Schwartz J, Pandit-Taskar N, Peak S, Divgi CR, Zelenetz AD, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer. 2007;110(11):2528\u201334.","journal-title":"Cancer"},{"issue":"18 Pt. 2","key":"1706_CR15","doi-asserted-by":"publisher","first-page":"5652s","DOI":"10.1158\/1078-0432.CCR-07-1060","volume":"13","author":"E Cooney-Qualter","year":"2007","unstructured":"Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed\/refractory CD20-positive non-Hodgkin\u2019s lymphoma: a Children\u2019s Oncology Group study. Clin Cancer Res. 2007;13(18 Pt. 2):5652s-s5660.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1706_CR16","doi-asserted-by":"publisher","first-page":"20518","DOI":"10.1038\/s41598-020-77397-0","volume":"10","author":"AM Jarrett","year":"2020","unstructured":"Jarrett AM, Hormuth AD, Adhikarla V, Sahoo P, Abler D, Tumyan L, et al. Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Sci Rep. 2020;10(1):20518.","journal-title":"Sci Rep"},{"issue":"6","key":"1706_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMoa1704827","volume":"378","author":"T Sato","year":"2018","unstructured":"Sato T, Coler-Reilly ALG, Yagishita N, Araya N, Inoue E, Furuta R, et al. Mogamulizumab (anti-CCR4) in HTLV-1-associated myelopathy. N Engl J Med. 2018;378(6):529\u201338.","journal-title":"N Engl J Med"},{"issue":"2","key":"1706_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/infdis\/jiu438","volume":"211","author":"J Yamauchi","year":"2015","unstructured":"Yamauchi J, Coler-Reilly A, Sato T, Araya N, Yagishita N, Ando H, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015;211(2):238\u201348.","journal-title":"J Infect Dis"},{"issue":"6","key":"1706_CR19","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1182\/blood.V86.6.2350.bloodjournal8662350","volume":"86","author":"K Imada","year":"1995","unstructured":"Imada K, Takaori-Kondo A, Akagi T, Shimotohno K, Sugamura K, Hattori T, et al. Tumorigenicity of human T-cell leukemia virus type I-infected cell lines in severe combined immunodeficient mice and characterization of the cells proliferating in vivo. Blood. 1995;86(6):2350\u20137.","journal-title":"Blood"},{"issue":"8","key":"1706_CR20","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood.V82.8.2501.2501","volume":"82","author":"A Kondo","year":"1993","unstructured":"Kondo A, Imada K, Hattori T, Yamabe H, Tanaka T, Miyasaka M, et al. A model of in vivo cell proliferation of adult T-cell leukemia. Blood. 1993;82(8):2501\u20139.","journal-title":"Blood"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01706-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01706-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01706-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T17:03:17Z","timestamp":1646413397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01706-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,16]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01706-4","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,16]]},"assertion":[{"value":"2 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}